Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VARIANT-ADAPTED BNT162b2 RNA-BASED VACCINE CANDIDATE(S) IN HEALTHY CHILDREN

NCT05543616 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT05543616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05543616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VARIANT-ADAPTED BNT162b2 RNA-BASED VACCINE CANDIDATE(S) IN HEALTHY CHILDREN
Lead sponsor
BioNTech SE
Phase
Phase 3
Overall status
Completed
Start date
September 23, 2022
Completion date
July 10, 2026
Enrollment
4,338 (actual)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 virus, severe acute respiratory syndrome coronavirus 2